Please add the following new claims:

Sub B1

--57. A composition containing a T4 surface lattice protein array and a chimera comprising a molecule of interest, a T4 dispensable polypeptide and a linker, wherein the linker links the molecule of interest to the T4 dispensable polypeptide and wherein said chimera is bound to the T4 surface lattice protein array.

58. The composition of claim 57, wherein the molecule of interest is an antigen.

59. The composition of claim 57, wherein the molecule of interest is an enzyme.

60. The composition of claim 57, wherein the molecule of interest is an immunoglobulin.

61. The composition of claim 57, wherein the molecule of interest is a polypeptide.

62. The composition of claim 61, wherein the polypeptide consists of 4 or more amino acids.

Sub B2

63. The composition of claim 57, wherein the dispensable polypeptide is derived from a member of the T4 virus family that encodes a dispensable polypeptide.

64. The composition of claim 57, wherein the dispensable polypeptide is a T4 small outer capsid polypeptide (SOC).

65. The composition of claim 57, wherein the dispensable polypeptide is a T4 highly antigenic outer capsid polypeptide (HOC).

66. The composition of claim 57, wherein at least 100 copies of the molecule of interest are displayed on the T4 surface lattice protein array.

67. The composition of claim 57, wherein the linker comprises at least one amino acid residue.

68. A method of making the composition of claim 57 comprising:

contacting the T4 surface lattice protein array with the chimera comprising the molecule of interest, the T4 dispensable polypeptide and the linker.

69. The method of claim 68, wherein the molecule of interest is an antigen.

70. The method of claim 68, wherein the molecule of interest is an enzyme.

71. The method of claim 68, wherein the molecule of interest is an immunoglobulin.

72. The method of claim 68 wherein the molecule of interest is a polypeptide.

73. The method of claim 72, wherein the polypeptide consists of 4 or more amino acids.

74. The method of claim 68, wherein the dispensable polypeptide is derived from a member of the T4 virus family that encodes a dispensable polypeptide.

75. The method of claim 68, wherein the dispensable polypeptide is a T4 small outer capsid polypeptide (SOC).

76. The method of claim 68, wherein the dispensable polypeptide is a T4 highly antigenic outer capsid polypeptide (HOC).

77. The method of claim 68, wherein at least 100 copies of the molecule of interest are displayed on the T4 surface lattice protein array.

78. The method of claim 68, wherein the linker comprises at least one amino acid residue.

79. A method of making the composition of claim 57, comprising:

integrating into the genome of a virion from which all or part of the nucleic acid encoding a wild type T4 dispensable polypeptide has been deleted a chimeric nucleic acid molecule encoding the chimera comprising a nucleic acid sequence encoding the T4 dispensable polypeptide, a nucleic acid encoding the molecule of interest and a nucleic acid encoding the linker.

80. The method of claim 79, wherein the molecule of interest is an antigen.

81. The method of claim 79, wherein the molecule of interest is an enzyme.

82. The method of claim 79, wherein the molecule of interest is an immunoglobulin.

83. The method of claim 79, wherein the molecule of interest is a polypeptide.

84. The method of claim 83, wherein the polypeptide consists of 4 or more amino acids.

85. The method of claim 79, wherein the dispensable polypeptide is derived from a member of the T4 virus family that encodes a dispensable polypeptide.

86. The method of claim 79, wherein the dispensable polypeptide is a T4 small outer capsid polypeptide (SOC).

87. The method of claim 79, wherein the dispensable polypeptide is a T4 highly antigenic outer capsid polypeptide (HOC).

88. The method of claim 79, wherein at least 100 copies of the molecule of interest are displayed on the T4 surface lattice protein array.

89. The method of claim 79, wherein the linker comprises at least one amino acid residue.

90. A method of immunizing a mammal comprising:

administering to the mammal the composition of claim 57.

91. The method of claim 90, wherein the molecule of interest is an antigenic polypeptide.

92. A method of treating a mammal having a disorder associated with aberrent expression or activity of a biological molecule, the method comprising:

administering to the mammal the composition of claim 57.

93. The method of claim 92, wherein the molecule of interest binds to the biological molecule.